Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...

Please provide your email address to receive an email when new articles are posted on . Treatment with tenecteplase in an Australian mobile stroke unit was safe and resulted in improved outcomes ...

Intravenous (IV) tenecteplase works just as well as IV alteplase in patients with large-vessel occlusion (LVO) stroke who are eligible for thrombolysis, new research shows. In a prespecified secondary ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

The bolus thrombolytic, tenecteplase, was non-inferior to alteplase, which is given by a bolus followed by an infusion, for functional outcomes in acute ischemic stroke patients treated within 4½ ...

DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial ...

Ischemic strokes occur when there is blocked blood flow to the brain, something that can result in permanent disability. Doctors can use certain medications to dissolve blood clots when they are the ...

For people with ischemic stroke, treatment with the clot-busting drug tenecteplase is associated with a slightly higher likelihood of an excellent recovery and reduced disability three months later ...

PHOENIX -- Selected stroke patients did not benefit clinically from having the window of tenecteplase therapy extended beyond the first few hours of stroke onset, the randomized TIMELESS trial found.

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase seems to ...